Ser80
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser80  -  CDC42EP4 (human)

Site Information
SskRsLLsRKFRGSK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 35524901

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PKCA (human) ( 1 )
Kinases, in vitro:
PKCA (human) ( 1 )
Treatments:
DAG-lactone ( 1 )

Downstream Regulation
Effects of modification on CDC42EP4:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
cell motility, induced ( 1 ) , cytoskeletal reorganization ( 1 )
Induce interaction with:
ARHGEF17 (human) ( 1 ) , PARD6G (human) ( 1 )
Inhibit interaction with:
CDC42 (human) ( 1 )

References 

1

Zhao X, Rotenberg SA (2014) Phosphorylation of Cdc42 effector protein-4 (CEP4) by protein kinase C promotes motility of human breast cells. J Biol Chem 289, 25844-54
25086031   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info